MediWound (NASDAQ:MDWD) Shares Cross Below 200 Day Moving Average – Should You Sell?

MediWound Ltd. (NASDAQ:MDWD)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $15.72 and traded as low as $12.85. MediWound shares last traded at $12.97, with a volume of 80,358 shares.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MDWD shares. Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $33.00.

MediWound Price Performance

The firm has a market cap of $170.13 million, a PE ratio of -7.36 and a beta of 0.15. The business has a fifty day moving average price of $14.21 and a two-hundred day moving average price of $15.69.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The company had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $2.59 million. As a group, sell-side analysts forecast that MediWound Ltd. will post -2.31 EPS for the current fiscal year.

Insider Buying and Selling

In other MediWound news, Director David Morton Fox purchased 3,537 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were acquired at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the acquisition, the director owned 22,283 shares of the company’s stock, valued at $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 9.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers increased its stake in MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 481 shares during the period. Russell Investments Group Ltd. lifted its position in shares of MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 649 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound by 22.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of MediWound during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.